Golimumab

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis

Trial Timeline

Sep 3, 2012 → Apr 30, 2015

NCT ID

NCT01668004

About Golimumab

Golimumab is a approved stage product being developed by Merck for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01668004. Target conditions include Ankylosing Spondylitis.

What happened to similar drugs?

11 of 20 similar drugs in Ankylosing Spondylitis were approved

Approved (11) Terminated (4) Active (8)

🔄adalimumabEisaiPhase 3

❌Ixekizumab + Placebo + AdalimumabEli LillyPhase 3

✅Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved

🔄Golimumab + PlaceboJohnson & JohnsonPhase 3

✅GolimumabJohnson & JohnsonApproved

✅AdalimumabAbbVieApproved

🔄infliximab + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03270501	Phase 3	Completed	Nov 8, 2017	Dec 14, 2023	Axial Spondyloarthritis
NCT03124121	Approved	Completed	Sep 5, 2017	Sep 30, 2019	Ulcerative Colitis
NCT02841176	Pre-clinical	Terminated	Jul 1, 2016	Sep 19, 2017	Psoriatic Arthritis
NCT02318667	Approved	Completed	Feb 27, 2015	Sep 5, 2017	Colitis, Ulcerative
NCT02092285	Approved	Completed	May 9, 2014	May 25, 2016	Ulcerative Colitis
NCT01668004	Approved	Completed	Sep 3, 2012	Apr 30, 2015	Ankylosing Spondylitis

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors

Product	Company	Stage	Hype Score
Infliximab	Celltrion	Phase 1	29
Infliximab	Celltrion	Phase 1	29
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
adalimumab	Eisai	Phase 3	40
Ixekizumab + Placebo + Adalimumab	Eli Lilly	Phase 3	32
Tramadol /acetaminophen + Diclofenac	Johnson & Johnson	Approved	35
Golimumab + Placebo	Johnson & Johnson	Phase 3	40
Golimumab	Johnson & Johnson	Approved	43
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 2/3	38
placebo for risankizumab + risankizumab	AbbVie	Phase 2	35
Adalimumab	AbbVie	Approved	39
Upadacitinib + Placebo	AbbVie	Phase 2	35
Adalimumab	AbbVie	Pre-clinical	26
infliximab + Placebo	Merck	Phase 3	40
Infliximab	Merck	Approved	35
Infliximab + Placebo + Naproxen	Merck	Phase 3	40
Infliximab	Merck	Pre-clinical	26
Remicade	Merck	Approved	43
Remicade	Merck	Approved	43
Infliximab	Merck	Approved	43